Edition:
United States

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

41.00USD
19 Oct 2018
Change (% chg)

$0.19 (+0.47%)
Prev Close
$40.81
Open
$40.80
Day's High
$41.13
Day's Low
$40.68
Volume
31,252
Avg. Vol
59,348
52-wk High
$68.57
52-wk Low
$28.54

Latest Key Developments (Source: Significant Developments)

Anika Therapeutics Q2 Earnings Per Share $0.68
Wednesday, 25 Jul 2018 04:05pm EDT 

Anika Therapeutics Inc ::ANIKA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $0.68.Q2 REVENUE $30.5 MILLION VERSUS I/B/E/S VIEW $27.9 MILLION.Q2 EARNINGS PER SHARE VIEW $0.33 -- THOMSON REUTERS I/B/E/S.ANIKA THERAPEUTICS - CURRENTLY DOES NOT EXPECT LICENSING, MILESTONE AND CONTRACT REVENUE OF $5.0 MILLION IN 2018.CONTINUES TO ANTICIPATE PRODUCT REVENUE TO BE FLAT FOR FULL YEAR OF 2018.TOTAL OPERATING EXPENSES ARE NOW EXPECTED TO BE IN LOW $90 MILLION RANGE FOR FULL YEAR OF 2018.  Full Article

Anika Therapeutics Says Trial Of Knee Osteoarthritis Drug Misses Main Goal
Tuesday, 19 Jun 2018 04:05pm EDT 

June 19 (Reuters) - Anika Therapeutics Inc ::ANIKA THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM CINGAL 16-02 CLINICAL TRIAL IN KNEE OSTEOARTHRITIS.ANIKA THERAPEUTICS INC - CINGAL 16-02 STUDY DID NOT ACHIEVE STATISTICAL SIGNIFICANCE AT PRIMARY ENDPOINT OF 26 WEEKS.ANIKA-CINGAL ACHIEVED GREATER PAIN REDUCTION NUMERICALLY AT EVERY TIME POINT IN STUDY, DIFFERENCE AT 26-WEEKS DID NOT REACH STATISTICAL SIGNIFICANCE.ANIKA-STRONG PAIN REDUCTION,OVERALL SYMPTOM RELIEF CONSISTENT WITH STATISTICALLY SIGNIFICANT RESULTS OF CINGAL 13-01 PHASE III PLACEBO-CONTROLLED STUDY.  Full Article

Anika Therapeutics Announces $30 Mln Accelerated Share Repurchase
Wednesday, 23 May 2018 04:05pm EDT 

May 23 (Reuters) - Anika Therapeutics Inc ::ANIKA THERAPEUTICS ANNOUNCES $30 MILLION ACCELERATED SHARE REPURCHASE.ANIKA THERAPEUTICS INC - PLANS TO UTILIZE EXISTING CASH ON HAND TO FUND ASR PROGRAM.ANIKA THERAPEUTICS INC - EXPECTS THAT ASR PROGRAM WILL COMMENCE IN LATE MAY AND THAT IT WILL BE COMPLETED IN Q4 OF 2018.  Full Article

Joseph Darling Named CEO And Director Of Anika Therapeutics
Monday, 5 Mar 2018 04:02pm EST 

March 5 (Reuters) - Anika Therapeutics Inc ::JOSEPH DARLING NAMED CEO AND DIRECTOR OF ANIKA THERAPEUTICS.ANIKA THERAPEUTICS - DARLING TO SUCCEED CHARLES SHERWOOD, WHO WILL RETIRE AS CEO AND A DIRECTOR OF ANIKA ON MARCH 9, 2018.  Full Article

Anika Q4 Earnings Per Share $0.53
Wednesday, 21 Feb 2018 04:05pm EST 

Feb 21 (Reuters) - Anika Therapeutics Inc ::ANIKA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.53.Q4 REVENUE $29.4 MILLION VERSUS $28.7 MILLION.COMPANY EXPECTS TOTAL REVENUE GROWTH TO BE AROUND MID-SINGLE DIGIT PERCENTAGE RANGE FOR FULL YEAR OF 2018.  Full Article

Anika reports Q3 earnings per share $0.46
Wednesday, 25 Oct 2017 04:05pm EDT 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika reports third quarter 2017 financial results.Q3 earnings per share $0.46.Q3 revenue rose 5 percent to $27.2 million.  Full Article

Anika completes enrollment in second pivotal phase III trial of cingal
Wednesday, 25 Oct 2017 04:04pm EDT 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika Therapeutics - ‍Anika expects to complete cingal second pivotal phase III trial in first half of 2018 and anticipates FDA approval following year​.  Full Article

Anika Therapeutics announces regulatory approval for Monovisc® in Australia
Monday, 16 Oct 2017 04:05pm EDT 

Oct 17 (Reuters) - Anika Therapeutics Inc :Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints.Anika Therapeutics Inc - ‍Anika intends to further expand Monovisc into additional international markets in 2018​.  Full Article

Anika announces appointment of Joseph Darling as president
Thursday, 27 Jul 2017 08:05am EDT 

July 27 (Reuters) - Anika Therapeutics Inc :Anika announces appointment of joseph darling as president.Anika therapeutics - co's ceo dr. Charles h. Sherwood who served as president, plans to transition role to darling, while continuing tenure as ceo.  Full Article

Anika reports Q2 earnings per share $0.76
Wednesday, 26 Jul 2017 04:05pm EDT 

July 26 (Reuters) - Anika Therapeutics Inc :Anika reports strong second quarter 2017 financial results.Q2 earnings per share $0.76.Q2 revenue $33.5 million versus I/B/E/S view $27.2 million.Q2 earnings per share view $0.44 -- Thomson Reuters I/B/E/S.Anika Therapeutics Inc says company plans to expand into India, Australia, and New Zealand over next six to nine months.Anika Therapeutics Inc says receiving regulatory approval for Monovisc in India for treatment of pain associated with osteoarthritis of all human synovial joints.  Full Article